INTRODUCTION
Psoriasis (Ps) affects an estimated 7.4 million adults (3.2% of the total population) in the US [1] . Nearly one in three psoriasis patients will develop psoriatic arthritis (PsA) [2, 3] , a chronic inflammatory arthropathy typically associated with Ps of the skin or nails and includes other manifestations such as enthesitis, dactylitis, uveitis, and spondylitis [4] . Given the progressive nature of the disease, nearly half of PsA patients will develop irreversible bone erosions/joint destruction [5] Additionally, an indirect comparison of RCT data found that apremilast has similar efficacy to MTX in treating a MTX-naïve population [23] . Both TNFis and the PDE4i have been recommended by GRAPPA as treatment options after initial DMARD failure. However, it is not clear whether using apremilast or a TNFi first may have different clinical and/or economic impacts on patient outcomes. Use of apremilast after DMARD failure may result in a delay in prescribing TNFis known to reduce structural progression. The current study was designed to robustly model the economic impact of timely versus delayed use of TNFis in patients with moderately to severely active
PsA with/without moderate/severe Ps from a US payer's perspective.
METHODS

Model Overview
This economic evaluation was performed using a Approximately 20% of patients in these trials had previously received TNFis, while all patients in ADEPT; NCT00195689 were biologic-naive [30] . Because limited information was available regarding efficacy in a biologic-naïve population, the base case model was conducted based on the efficacy noted in all patients in PALACE 1-3, and sensitivity analyses were conducted using ACR20 responses among biologic-naïve patients reported in PALACE 1 [16] and 3 [20] .
Clinical efficacy at month 3 was then translated into improvements in HAQ scores relative to baseline ( 
Subsequent-Line
Effectiveness In non-responders or patients who lost ACR20 [32] . Reduction in short-term responses were estimated as 25, 27 and 37% relative to first-line ACR20, ACR50
and ACR70 responses, respectively [32] . On the other hand, there is no evidence regarding the effectiveness of delayed TNFi use following apremilast failure-a decrease in efficacy was assumed. This was based on observations from rescue treatment in the ADEPT trial and its open-label 48-week extension, which suggested that patients who initially received TNFis experienced better outcomes than those originally randomized to receive placebo and then received the TNFis [26, 27] . The efficacy of TNFi after apremilast was assumed to decrease by 21, 14 and 8% for ACR20, ACR50 and ACR70 respectively, again based on the rescue arm of the ADEPT RCT [26, 27] .
Treatment Withdrawal Based on real-world observations of treatment discontinuation and switching, the model assumed a certain risk of withdrawal from TNFi therapy after each cycle, due to loss of efficacy, adverse events or other reasons. Withdrawal rates for first and subsequent line TNFi use were obtained from a British registry study and assumed to be constant over time (Table 2 ) [33] . As long-term real-world withdrawal rates have not yet been reported for apremilast, they were assumed to be the same as for TNFis. When patients withdrew from treatment, HAQ scores were assumed to rebound to baseline levels and patients were moved to the next line of treatment at the beginning of the next cycle.
Outcomes for Symptomatic Care For patients who failed a subsequent-line TNFi, the model placed these patients in symptomatic care. This was based on the York model [24] , given that treatment guidelines at the time of this analysis did not have recommendations past second-line treatment with TNFi biologics [25, 34, 35] . For patients who failed TNFi treatment, the model assumed that their HAQ score would continue to deteriorate from the last value assigned on subsequent-line treatment at a rate of 0.018 per cycle-based on an assumption of inefficacy with subsequent DMARD treatment for PsA symptoms, as suggested by clinical expert opinion [31] .
Mortality Since PsA patients are known to have an increased risk of death compared with the general population [36] , an additional mortality risk of 65% for males and 59% for females [36] was considered for PsA when estimating mortality and the model assumed no difference in mortality rates between treatments.
Effectiveness in Treating Psoriasis
TNFis are approved to treat both joint and skin disease. A subgroup analysis examined clinical improvement, measured by 75% improvement in PASI as well as ACR20 at each Markov cycle.
Effectiveness for both skin and joint manifestations was modeled in this previously defined subgroup. Since there is a positive correlation between responses (e.g., ACR responders are more likely to be PASI responders [37] [38] [39] [40] ), a bivariate evidence synthesis was performed. Correlations between PASI75 and ACR20 responses were again derived from the ADEPT trial [26] and used to estimate the probability a patient would have both joint and skin responses ( Table 2 ). This same correlation was used across all treatment groups, assuming the relationship between joint and skin responses are independent of the treatment patients received (as known for TNFis) [24] .
Costs
Based on a third-party payer's perspectives, the base case model considered only direct costs, including treatment-related (product, administration, and monitoring costs) and other medical costs (Table 3) . The model assumed that PsA patients incurred other medical costs for inpatient and outpatient visits and that costs would increase with severity of arthritis and/or psoriasis [43] . Due to the lack of economic studies on medical costs by HAQ in PsA, the health service costs of treating arthritis were derived from a US-based study that estimated the effect of HAQ on direct costs in patients with RA [43] . The study reported total direct costs corresponding to quartiles of HAQ scores, with 75% attributed to medical services. A weighted linear regression was fitted using the mid-point of the HAQ score as an independent variable and other medical costs as the dependent variable, weighted by the number of patients in each quartile. This coefficient was estimated to be $1040, the mean change in 3-month cost for a 1-unit change in HAQ. Medical costs of treating PsA were estimated as a function of HAQ score at of the analysis; 3% discounting rates for both effectiveness and costs were considered when varying time horizon to 5 years in the sensitivity analyses.
Model Outputs
The base case model estimated total direct costs and effectiveness for each treatment sequence at 1 year after treatment initiation. Among patients with PsA, effectiveness was measured by joint responses (ACR20) and mean time as an ACR20 responder at year 1. Among patients with both joint and skin manifestations, treatment effectiveness was measured by combined ACR20 ? PASI75 responses and mean time as ACR20 ? PASI75 responders.
Numbers needed to treat (NNT) for achievement of ACR20 or ACR20 ? PASI75 responses were also reported.
Based on effectiveness and costs outputs, costs per responder for each treatment sequence were calculated. Incremental costs per responder measured the costs per ACR20 (or ACR20 ? PASI75) responders with timely vs. delayed use of TNFi.
Sensitivity Analyses
One-way sensitivity analyses were conducted to examine the impact of change in one key model input or assumption, while holding others at base case values. Model inputs that were varied include treatment costs, other medical costs, efficacy, treatment withdrawal rate, baseline patient characteristics, mortality rate, and time horizon. In addition, the societal perspective, considering both direct and indirect costs, was modeled in sensitivity analyses-indirect costs were estimated as a function of HAQ, based on the similar approach for medical costs. Since no US studies were found to estimate indirect costs associated with PsA, the number of working days missed due to RA were obtained from a German study [45] and the average wage per day in the US [46] was applied to estimate total indirect costs associated with given HAQ scores.
A detailed list of parameters and corresponding ranges/assumptions of the one-way sensitivity analyses are provided in Fig. 2 .
The model and sensitivity analyses were conducted using Excel 2010 (Microsoft Corporation, Redmond, WA).
Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors. (Table 4b) .
RESULTS
Base Case Analysis
One-Way Sensitivity Analyses
In the one-way sensitivity analyses, incremental cost per ACR20 responder ranged from $51,274 to $116,624. Factors with the largest impact on incremental costs were treatment-related costs, apremilast ACR20 responses at 12 weeks, and a longer time horizon (i.e., 5 years). Incremental costs per ACR20 ? PASI75 responders ranged from $51,760 to $91,822 and were most sensitive to treatment-related costs, indirect costs, and a longer time horizon (Fig. 2) and concluded that apremilast is a more cost-effective option over a lifetime horizon [55] , with lower costs per responder relative to TNFis in a one-year treatment model [56] .
However, from the available published information, these previously published models did not consider concomitant Ps or structural progression in PsA, and still produced only modest cost savings with the use of apremilast.
In the present economic model, patients initially treated with a TNFi had higher responses and lower NNTs than those initially receiving apremilast. Although patients with timely use of a TNFi had higher treatment-related costs than the delayed use group after 1 year, these costs were partially offset by lower other medical costs. Based on costs-per-responder estimates, total annual costs for ACR20 responders were similar in both groups, although slightly higher with ACR20 American College of Rheumatology 20% response; PASI Psoriasis Area Severity Index; PsA psoriatic arthritis; TNFi Tumor Necrosis Factor inhibitors a Number needed to treat is defined as the average number of patients who need to be treated for one responder. The comparison results (in italics) between the two arms should be interpreted as the number of patients who need to be treated to observe one responder in arm A versus arm B timely use. When both joint and skin responses were accounted for, responses and cost trends were similar to analyses that were based on joint responses only, but total costs were much lower for timely use vs. delayed use of TNFis. These results indicate that, overall, timely treatment with TNFis is more expensive than delayed treatment, but for those patients with both skin and joint manifestations, cost savings can be substantial. Since 46-83% patients enrolled in TNFi RCTs [57] have manifestations of Ps, this finding underscores the need to consider effectiveness for both joint and skin disease when assessing treatments for PsA.
This study provides important information on economic and clinical outcomes associated with choice of TNFis versus apremilast as 1st-line treatment for moderately to severely active PsA, with careful attention to presenting an accurate model of the disease. Nonetheless, this still remains a model, which cannot account for the natural history of the disease or all aspects of its treatment. Sensitivity analyses were performed to identify largest areas of uncertainty [58] in the model-indicating that, among other factors, ACR20 responses with apremilast treatment and 1st-line withdrawal rates following apremilast had a large impact on the model results. Due to lack of available information, some assumptions were necessary to incorporate into the model: ACR20 responses were derived from RCTs with apremilast that included mixed populations of treatment-naïve and TNFi-exposed patients.
Based on reported efficacy, it is possible that treatment-naïve patients receiving apremilast might achieve higher responses than in the mixed population trials-although ACR20 rates at week 14 were 28-31% in the PALACE 4 trial (NCT01307423) in DMARD (synthetic and biologic)-naïve patients [59] , below those observed in PALACE 1-3 (which were used in the present analysis). Therefore, sensitivity analyses were conducted to include a compensatory factor for ACR20 responses with apremilast, increasing response rates from the observed 37% to an estimated 43%, based on the subgroup analysis in biologic-naïve patients, as reported in PALACE 1 and 3. Furthermore, since there is no information regarding the degree to which the effectiveness of TNFis may be impacted by prior use of apremilast, the model used rescue data from RCTs to estimate the difference between timely vs. delayed initiation of a TNFi. Nonetheless, the effect of this latter adjustment on the primary findings was not substantial, and the model assumed the same withdrawal rates for the two treatment sequences, as there were no long-term observational data with apremilast.
Despite these sensitivity analyses, several limitations of the current model must be Finally, uncertainty [62] remains regarding progression of HAQ scores with and without TNFi and apremilast treatment and their short-term effectiveness in PsA. Further research is needed on these topics, as all current cost-effectiveness models of treatment for PsA rely on assumptions for these inputs [24] . 
CONCLUSION
